Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 145

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 145
---
 | (81,112 | ) |

<div align='center'>109</div>

Series M Preferred of Zander Therapeutics, Inc.

On November 29, 2018, the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $13,124.

| Basis |         |     | Fair Value |        |     | Total Unrealized Gains/(Loss) |          |   |
|:------|--------:|:----|:-----------|-------:|:----|:------------------------------|:---------|:--|
| $     | 134,971 |     | $          | 11,238 |     | $                             | (123,733 | ) |

On September 30, 2024, the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs:

|                                                          |     | As of September 30, |       2024 |   |     |   |       2023 |   |
|:---------------------------------------------------------|:----|:--------------------|-----------:|:--|:----|:--|-----------:|:--|
| Fair Value of Intellectual Property                      |     | $                   |    300,000 |   |     | $ |      1,500 |   |
| Prepaid Expenses                                         |     |                     |     65,661 |   |     |   |     65,661 |   |
| Due from Employee                                        |     |                     |          - |   |     |   |      1,071 |   |
| Note Receivable                                          |     |                     |      40000 |   |     |   |     64,400 |   |
| Accrued Interest Receivable                              |     |                     |     35,000 |   |     |   |     23,989 |   |
| Investment Securities                                    |     |                     |    258,255 |   |     |   |  8,423,366 |   |
| Convertible Note Receivable                              |     |                     |     10,000 |   |     |   |     10,000 |   |
| Accounts Payable                                         |     |                     |     30,563 |